Cordyceps sinensis relieves non-small cell lung cancer by inhibiting the MAPK pathway

• Published in: Chinese medicine Vol. 19; no. 1; pp. 54 - 14
• Main Authors: Lu, Tianming, Zhou, Lirun, Chu, Zheng, Song, Yang, Wang, Qixin, Zhao, Minghong, Dai, Chuanhao, Chen, Lin, Cheng, Guangqing, Wang, Jigang, Guo, Qiuyan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.03.2024; BioMed Central; BMC
• Subjects: Adenosine; Animal models; c-Fos protein; Cancer; Cancer therapies; CD4 antigen; CD8 antigen; Cell activation; Cell differentiation; Cell proliferation; Combination therapy; Cordyceps Sinensis; Dendritic cells; Drug dosages; Enzymes; Fluorescence; Glutathione peroxidase; Granulocyte-macrophage colony-stimulating factor; Health aspects; Immune response; Inflammation; Interleukin 10; Interleukin 6; Interleukins; Kinases; Laboratory animals; Leukocyte migration; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Lymphocytes; Lymphocytes T; MAP kinase; MAPK pathway; Mass spectrometry; Molecular modelling; Natural killer cells; Non-small cell lung carcinoma; NSCLC; Oncology, Experimental; Oxidative stress; Pharmaceuticals; Pharmacodynamics; Proteins; Proteomics; Raf protein; Scientific imaging; Superoxide; Transcriptomics; Tumor necrosis factor; Tumor necrosis factor-TNF; Vascular endothelial growth factor; China; Beijing China; United States > US; MAPK pathway; Cordyceps Sinensis; NSCLC; Transcriptomics; Proteomics

To determine the pharmacodynamic mechanism underlying Cordyceps sinensis relief in a murine model of non-small cell lung cancer (NSCLC). We created a murine model of NSCLC and studied the potential molecular mechanism by which C. sinensis relieved NSCLC using a combination of transcriptomics, proteo...